Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr-Abl that is intended to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Hansoh Pharm's research and development in Flumatinib has lasted for more than 10 years. In September 2006, the company submitted the application for clinical trial 1.1 clinical trial for the first time, and approved the clinical trial in August 2007. In 2008, it was supported by major national science and technology projects. In 2012, it was supported by the specialization of scientific and technological achievements in Jiangsu Province. In July 2018, Hansoh Pharm submitted the production application, Flumatinib becoming the first declared second-generation Bcr-Abl tyrosine kinase (TKI) inhibitor of production in China. It was included in the priority review process on the basis of innovative drugs with obvious therapeutic advantages in September.